Mersana Therapeutics Selloff on Data Overdone, Says BTIG
Buy Rating for Mersana Therapeutics: Promising Efficacy and Safety of Emi-Le ADC Amid Stock Price Volatility
12 Health Care Stocks Moving In Friday's Pre-Market Session
Wedbush Cuts Price Target on Mersana Therapeutics to $4 From $7, Keeps Outperform Rating
LifeSci Capital Maintains Mersana Therapeutics(MRSN.US) With Buy Rating, Maintains Target Price $8
Mersana Therapeutics Shares Are Trading Lower. The Company Announced Initial Clinical Data From the Phase 1 Dose Escalation and Backfill Cohorts for Emiltatug Ledadotin.
